The European Medicines Agency (EMA) has started to examine Russia's Sputnik V vaccine against Covid-19, the agency said in a statement Thursday.
The decision to start the rolling review is based on results from clinical studies in adults, which indicate that Sputnik V triggers the production of antibodies and immune cells that target the SARS-CoV-2 virus, and could help protect against Covid-19, EMA said in its press release.
EMA has started a rolling review of Sputnik V, a #COVID19vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology. ? https://t.co/pHVqmSMAuW pic.twitter.com/Bff87qJwOV
— EU Medicines Agency (@EMA_News) March 4, 2021
The Russian authorities already announced that they were ready to supply vaccines to the European Union if it approves the vaccine, reports the Belga news agency.
"Following approval by the EMA, we would be able to supply vaccines for 50 million Europeans from June 2021," Kirill Dmitriev, head of the Russian sovereign wealth fund which helped develop the vaccine, said in a statement on Thursday
The Brussels Times
